(Reuters) – Kenvue on Thursday reported higher third-quarter revenue, owing to strong demand for its self-care and skincare products such as Tylenol and Neutrogena.
The consumer health company reported revenue of $3.92 billion for the quarter ended Oct. 1, compared with $3.79 billion, a year earlier.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Shweta Agarwal)